IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)
Status and phase
Completed
Phase 3
Conditions
Osteoporosis
Treatments
Drug: risedronate
Details and patient eligibility
About
The primary objective of this study is to assess the impact of physician's reinforcement using bone marker data on the subject's compliance (at least 50% drug taken) and persistence on treatment after one year in postmenopausal osteoporotic women.
Sex
Female
Ages
65 to 80 years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Ambulatory women,
- Caucasian, Oriental or Multiracial
- not previously diagnosed for osteoporosis.
Exclusion criteria
- Females of black descent and for the US african american are excluded because of the very low incidence of postmenopausal osteoporosis
- and having used oral or parenteral glucocorticoids (>= 5 mg prednisone or equivalent per day) within 3 months of starting study drug or for more than one month within six months prior to study entry.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
None (Open label)
Trial contacts and locations
0
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems